NDAORAL-21TABLET
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
ALESSE (ethinyl estradiol; levonorgestrel) by Cadence Neuroscience. Approved for pregnancy. First approved in 1997.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALESSE is an oral contraceptive combining ethinyl estradiol and levonorgestrel, approved in 1997 for pregnancy prevention. It is a combined hormonal contraceptive tablet taken daily as part of a 21-day cycle, functioning as an estrogen/progestin regimen to prevent ovulation and thicken cervical mucus.
LOE Approaching
With LOE approaching and no active clinical pipeline noted, commercial teams face declining revenue and potential downsizing within the brand organization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
Observational Trial With Leios/Alesse
Started May 2005
Contraceptives, Oral, Combined
Career Relevance
Working on ALESSE offers limited career advancement due to its approaching loss of exclusivity and mature market position. Professionals on this team are likely managing decline and optimizing profitability rather than driving growth or innovation.
Worked on ALESSE at Cadence Neuroscience? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.